Prediction Value of BRCA1 for Platinum-based Chemotherapies Effect on Advanced Non-small Cell Lung Cancer Patients: A Meta-analysis

Objective  To evaluate the prediction value of BRCA1 for platinum-based chemotherapies effect on advanced non-small cell lung cancer(NSCLC) patients.

Methods  PubMed, CNKI and Wanfang database were all searched using a computer to collect clinical studies in accordance with the established inclusion and exclusion criteria regarding BRCA1 expression predicted the benefit from platinum-based chemotherapy on NSCLC. The deadline was July 2015. A RevMan 5.4.1 software was used for statistical analysis.

Results  A total of 19 case-control studies were included in the Meta-analysis. The results showed no associations between BRCA1 expression and the clinical outcomes of platinum-based chemotherapies on advanced NSCLC patients. The pooled OR was 0.80 (95%e: 0.54-1.17). The subgroup analysis based on ethnicity showed negative BRCA1 expression was in favor of better overall response rate (ORR) in the Asian.The subgroup analysis of the detection method showed BRCA1 expression levels detected by IHC or PCR had no correlation with the sensitivity to platinum-based chemotherapy on patients with advanced NSCLC. BRCA1 was not associated with PFS or OS benefit in advanced NSCLC patients.

Conclusion  There is no association between BRCA1 expression and the clinical outcomes of platinum-based chemotherapies on advanced NSCLC patients; however, further studies are needed to validate the conclusion.